Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
2(40%)
Results Posted
33%(1 trials)

Phase Distribution

Ph phase_3
2
40%
Ph phase_2
1
20%
Ph phase_1
2
40%

Phase Distribution

2

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
2(40.0%)
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
2(40.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

5

all time

Status Distribution
Active(2)
Completed(3)

Detailed Status

Completed3
Recruiting2

Development Timeline

Analytics

Development Status

Total Trials
5
Active
2
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (40.0%)
Phase 21 (20.0%)
Phase 32 (40.0%)

Trials by Status

completed360%
recruiting240%

Recent Activity

2 active trials
Showing 5 of 5
recruitingphase_2

A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.

NCT07219615
recruitingphase_3

A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata

NCT06873945
completedphase_3

An Efficacy and Safety of CNTO 1959 (Guselkumab) in Participants With Moderate to Severe Plaque-type Psoriasis

NCT02325219
completedphase_1

The Safety, Tolerability and Pharmacokinetic Study of ZSP1273 in Healthy Volunteers.

NCT03679143
completedphase_1

Study in Chinese Healthy Adults to Evaluate the Safety, Tolerability and Pharmacokinetics on ZSP1601, and the Effect of Food on ZSP1601 Pharmacokinetics

NCT03392779

Clinical Trials (5)

Showing 5 of 5 trials
NCT07219615Phase 2

A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.

Recruiting
NCT06873945Phase 3

A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata

Recruiting
NCT02325219Phase 3

An Efficacy and Safety of CNTO 1959 (Guselkumab) in Participants With Moderate to Severe Plaque-type Psoriasis

Completed
NCT03679143Phase 1

The Safety, Tolerability and Pharmacokinetic Study of ZSP1273 in Healthy Volunteers.

Completed
NCT03392779Phase 1

Study in Chinese Healthy Adults to Evaluate the Safety, Tolerability and Pharmacokinetics on ZSP1601, and the Effect of Food on ZSP1601 Pharmacokinetics

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5